Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of
acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by
Bristol-Myers Squibb
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consist ...
. It is a
precursor of
nitroxyl
Nitroxyl (common name) or azanone (IUPAC name) is the chemical compound HNO. It is well known in the gas phase. Nitroxyl can be formed as a short-lived intermediate in solution. Its conjugate base, NO−, the nitroxide anion, is the reduced form o ...
.
Cimlanod is a
prodrug
A prodrug is a pharmacologically inactive medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be ...
of CXL-1020.
A preliminary study showed efficacy in patients with class III and IV heart failure. A phase II clinical trial was completed in 2016.
References
Experimental drugs
Furans
Sulfonamides
{{cardiovascular-drug-stub